PolyPeptide Group AG (SWX:PPGNE)

Market Cap	1.46B +78.5%
Revenue (ttm)	423.58M +24.4%
Net Income	13.34M
EPS	0.41
Shares Out	n/a
PE Ratio	107.36
Forward PE	45.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,423
Open	43.95
Previous Close	43.90
Day's Range	43.90 - 43.95
52-Week Range	43.00 - 44.15
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 9, 2027

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1952
• Employees: 1,460
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: PPGNE

Financial Performance

In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 23, 2026

Data Sources Report a data error